Literature DB >> 29417213

The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma.

Mehmet Murat Uzel1, Ufuk Elgin2, Barış Boral3, Muharrem Çiçek4, Emine Şen2, Burçin Şener4, Pelin Yılmazbaş2.   

Abstract

PURPOSE: We aimed to investigate the effect of trabeculectomy on serum brain-derived neurotrophic factor (BDNF) levels. Our secondary goal was to compare serum and aqueous humor (AH) BDNF levels in primary open-angle glaucoma (POAG) and control subjects.
METHODS: This prospective, cross-sectional study consists of 20 eyes of with advanced-stage POAG who had trabeculectomy and 19 eyes of age- and sex-matched control healthy subjects who had cataract surgery. Serum and AH samples were obtained preoperatively in trabeculectomy group and control subjects. Serum samples were obtained at the third postoperative month in both groups.
RESULTS: The aqueous humor and serum levels of BDNF at the surgery day were found to be strongly positive correlated (r = 0.868; p < 0.001). Serum and AH BDNF levels of POAG cases were significantly lower than control subjects at the surgery day (respectively p = 0.038, p = 0.011). In POAG cases, serum BDNF levels significantly increased at the third month after trabeculectomy while there was not a significant difference in control subjects with cataract surgery (p < 0.001; p = 0.717 respectively).
CONCLUSION: Trabeculectomy was found to have a positive effect on serum BDNF levels in POAG cases.

Entities:  

Keywords:  Brain-derived neurotrophic factor; Primary open-angle glaucoma; Trabeculectomy

Mesh:

Substances:

Year:  2018        PMID: 29417213     DOI: 10.1007/s00417-018-3923-y

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  26 in total

1.  Improvement in colour vision parameters following successful trabeculectomy.

Authors:  Leopoldo Magacho; Jeffrey D Henderer; Dara Lankaranian; William C Steinmann; George L Spaeth
Journal:  Acta Ophthalmol Scand       Date:  2006-04

2.  Brain-derived neurotrophic factor as a biomarker in primary open-angle glaucoma.

Authors:  Alireza Ghaffariyeh; Nazafarin Honarpisheh; Mohammad Hossein Heidari; Sadollah Puyan; Fuad Abasov
Journal:  Optom Vis Sci       Date:  2011-01       Impact factor: 1.973

3.  Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes.

Authors:  Matthew M Harper; Sinisa D Grozdanic; Bas Blits; Markus H Kuehn; Daniel Zamzow; Janice E Buss; Randy H Kardon; Donald S Sakaguchi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

Review 4.  Neurotrophic factor delivery as a protective treatment for glaucoma.

Authors:  Thomas V Johnson; Natalie D Bull; Keith R Martin
Journal:  Exp Eye Res       Date:  2010-06-01       Impact factor: 3.467

5.  Transport of brain-derived neurotrophic factor across the blood-brain barrier.

Authors:  W Pan; W A Banks; M B Fasold; J Bluth; A J Kastin
Journal:  Neuropharmacology       Date:  1998-12       Impact factor: 5.250

6.  Brain-derived neurotrophic factor in patients with normal-tension glaucoma.

Authors:  Alireza Ghaffariyeh; Nazafarin Honarpisheh; Yadollah Shakiba; Sadollah Puyan; Tooraj Chamacham; Farzad Zahedi; Mojtaba Zarrineghbal
Journal:  Optometry       Date:  2009-11

7.  Persistence of intact retinal ganglion cell terminals after axonal transport loss in the DBA/2J mouse model of glaucoma.

Authors:  Matthew A Smith; Christina Z Xia; Christine M Dengler-Crish; Kelly M Fening; Denise M Inman; Brett R Schofield; Samuel D Crish
Journal:  J Comp Neurol       Date:  2016-05-03       Impact factor: 3.215

8.  Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.

Authors:  Yuji Takihara; Masaru Inatani; Mikiko Fukushima; Keiichiro Iwao; Minako Iwao; Hidenobu Tanihara
Journal:  Am J Ophthalmol       Date:  2009-02-05       Impact factor: 5.258

9.  Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages.

Authors:  Francesco Oddone; Gloria Roberti; Alessandra Micera; Anna Busanello; Stefano Bonini; Luciano Quaranta; Luca Agnifili; Gianluca Manni
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

10.  Long-Term Protection of Retinal Ganglion Cells and Visual Function by Brain-Derived Neurotrophic Factor in Mice With Ocular Hypertension.

Authors:  Liang Feng; Hui Chen; Ji Yi; John B Troy; Hao F Zhang; Xiaorong Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

View more
  3 in total

1.  Tyrosine triple mutated AAV2-BDNF gene therapy in an inner retinal injury model induced by intravitreal injection of N-methyl-D-aspartate (NMDA).

Authors:  Asaka Lee Shiozawa; Tsutomu Igarashi; Maika Kobayashi; Kenji Nakamoto; Shuhei Kameya; Shigeto Fujishita; Hiroshi Takahashi; Takashi Okada
Journal:  Mol Vis       Date:  2020-06-03       Impact factor: 2.367

Review 2.  Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: Current Concepts and Future Directions.

Authors:  Jess Rhee; Kendrick Co Shih
Journal:  Biomolecules       Date:  2021-04-15

3.  Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling.

Authors:  Andrew Osborne; Tasneem Z Khatib; Lalana Songra; Amanda C Barber; Katie Hall; George Y X Kong; Peter S Widdowson; Keith R Martin
Journal:  Cell Death Dis       Date:  2018-09-26       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.